Based on current evidence, our results are the first to demonstrate that human GBM-cells are quite responsive in reducing the proliferation-rate of GBM-cells to first-/second-generation of SSAs [octreotide (mainly targeting SSTR2, with moderate affinity for SSTR5 and weak interaction with SSTR3 [68]) and pasireotide (a multi-SSTR agonist with high binding affinity for SSTR1/2/3/5 [68])], but not to SST and CORT (data not shown) or lanreotide (mainly targeting SSTR2 but with a slightly more pronounced affinity to SSTR5 compared with octreotide [68]). This evidence concerns the gene SSTR5 and glioblastoma.